Compare Tyson Foods, Inc. (TSN) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tyson Foods, Inc. vs Viatris Inc — how do they compare? Tyson Foods, Inc. trades at $57.25 (market cap $20.42B), while Viatris Inc trades at $17.58 (market cap $19.79B). The key difference: Tyson Foods, Inc. and Viatris Inc are close in size by market cap, and Tyson Foods, Inc. pays the higher dividend (3.52%). Which is the better fit depends on your goals.
| TSN | VTRS | |
|---|---|---|
Market Cap | $20.42B | $19.79B |
Sector | Consumer Staples | Health |
52-Week High | $68.75 | $17.39 |
52-Week Low | $50.72 | $8.74 |
Enterprise Value | $28.01B | $32.00B |
Dividend Yield | 3.52% | 2.83% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
